No Data
Positive Buy Rating for BridgeBio Pharma Backed by Strategic Initiatives and Upcoming Catalysts
BridgeBio Forms Joint Venture GondolaBio for Rare Disease Assets
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma: Positioned for Growth With Acoramidis' Market Potential and Positive Outlook Amidst Stabilized Expectations
Express News | BridgeBio Pharma Inc - Investors Have Committed $300 Mln of Tranched Financing to Gondolabio
Express News | BridgeBio Pharma - Entered Into Transaction Agreement Providing for Formation, Funding by Certain Third Party Investors of Gondolabio, LLC